Adult T-cell leukemia/lymphoma
Conditions
Interventions
None listed
Sponsors
Takeda Pharmaceutical Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria are eligible for this study: 1. Patients aged 18 years or older at the time of informed consent or the time of Opt-out confirmed 2. Patient who have given informed consent (verbal consent to participate in this study during enrolment period. For patients who have difficulty giving oral consent or who have died at the time of study registration, the patient who does not refuse to participate the study via optout ) will be enrolled. 3. Patient who have been diagnosed untreated CD30 positive ATL and received brentuximab vedotin+CHP
Exclusion criteria
Exclusion criteria: Patients who meet the following criteria will be excluded from this study: 1.Patients considered ineligible for the study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response Rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival Progression free survival Complete response rate Response rate by lesion site Disease control rate Time to treatment failure Time to next treatment Relative dose intensity Safety (Adverse Events) | — |
Countries
Japan
Contacts
Public ContactTakara Yamada
Linical Co.,Ltd. Contract Medical Affairs Unit, Clinical Trial Operations
Outcome results
None listed